The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Open accessAbstract
Combination of antiangiogenic treatment and immune checkpoint inhibition improves antitumor immunity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results suggest that the anticancer activity of the proposed DDS could promise to target Ang-2 supporting the immune checkpoints inhibition [89,91].”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [89]
In the citing paper
“In a study by Schmittnaegel et al., inhibition of Ang-2 together with vascular endothelial growth factor A (VEGFA) enhanced the antitumor immunity, allowing PD-1 checkpoint inhibition [89].”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [89]
In the citing paper
“We previously demonstrated that vascular normalization could increase immune cells’ infiltration into tumors, and multiple studies have confirmed these findings in several tumor models (15,17-19).”
In the citing paper
“An improved vascular network favors adaptive antitumor immunity by promoting trafficking and re-localization of tumor-infiltrating lymphocytes (TILs), leading to improved outcomes of various immunotherapies, including immune checkpoint blockade (ICB) (15-20).”
In the citing paper
“Lack of perfusion, tumoral hypoxia, and T-cell exclusion are considered significant resistance mechanisms (15,17-19).”
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 3×
“9, eaak9670 (2017) 12 April 2017 may be reminiscent of findings in cancer patients receiving immune checkpoint blockade: Although the antitumoral responses can be marked and long-lasting in some cases, they typically involve only a minority of the patients (17).”
BackgroundAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 1×
“Vascular endothelial growth factor A (VEGFA) is a key promoter of tumor angiogenesis (3).”
BackgroundModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2×
“The lack of durable antitumoral responses after VEGFA inhibition mirrors that of other targeted drugs and can be attributed, at least in part, to compensatory proangiogenic signaling, either induced or preexisting in tumors (4, 5).”
BackgroundVessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195 · cited 1×
“ANGPT2 neutralization might exacerbate vascular co-option by cancer cells (39), and there is also evidence that genetic Angpt2 deficiencymay aggravate the progression of colorectal liver metastasis in mice (40).”
BackgroundCancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049 · cited 1×
“9, eaak9670 (2017) 12 April 2017 which may be conducive to the activation of tumor-specific CD8 CTLs, and the phagocytic activity of tumor-associated APCs, which primarily stimulate CD4 T helper functions through MHCII-mediated antigen presentation (31).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · cited 2×
“For example, VEGFA can directly impair DC maturation, and neutralization of VEGFA enhances the antigen-presenting capacity of DCs in mouse tumor models (44, 45).”
BackgroundInduction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Other studies have suggested that a dual anti-angiogenic approach with a bi-specific anti-VEGF/Ang2 antibody potentiated the activity of anti-PD-L1 treatment in multiple models (Schmittnaegel et al., 2017).”
BackgroundMacrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
“Interestingly, a dual inhibitor of VEGFA and ANG2 (A2V or vanucizumab) improved vessel normalization in preclinical models (228), which is being evaluated in clinical trials (229).”
Metadata
- Authors
- Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., & De Palma, M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
- F. Hoffmann-La Roche AG (CH)
- Roche Pharma AG (Germany) (DE)
- Corresponding author
- Schmittnaegel, Martina
- Rigamonti, Nicolò
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-04-12
- Volume
- 9
- Issue
- 385
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2606765235
- Cited by
- 582
- References
- 66
- Citations by year
- 2026: 37 · 2025: 53 · 2024: 55 · 2023: 65 · 2022: 77 · 2021: 75 · 2020: 77 · 2019: 57 · 2018: 56 · 2017: 28
- FWCI
- 26.45
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Leenaards Foundation
- Swiss Cancer League (KFS-3007-08-2012, KFS-3759-08-2015)
- San Salvatore Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- angiopoietin-2, VEGF-A, antitumor immunity, anti-PD-1 therapy, PD-L1, tumor endothelial cells, cytotoxic T lymphocytes, interferon-gamma, anti-angiogenic therapy, immune checkpoint blockade, cancer immunotherapy
- MeSH terms
- Animals, Blood Vessels, Mice, Inbred C57BL, Mice, Transgenic, CD8-Positive T-Lymphocytes, Vascular Endothelial Growth Factor A, Angiopoietin-2, Cell Line, Tumor, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. https://app.cochat.ai/papers/10.1126/scitranslmed.aak9670
- The paper
- Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., & De Palma, M. (2017). Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aak9670
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.